Delivery Order SPE2DR25D1103-SPE2DR26FD760
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,674.11 to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors. This firm fixed-price delivery order, which is expected to be completed by November 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $17,770.68 on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 28, 2025, and performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $14,183.71. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract, valued at $1,709.46 with a firm fixed price structure, represents a non-set-aside competitive award. Performance will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 28, 2025. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp valued at $59,873.00 for the supply of Dupixent 300 mg/2 ml pen injectors on September 26, 2025. This firm fixed price, competitively awarded delivery order is scheduled for completion by September 29, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FD760Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $20,671.76 on November 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price contract with a completion date of November 5, 2025, and carries no set-aside designation. The contract represents a competitive award to support federal medical procurement needs, with AmerisourceBergen fulfilling the delivery obligation from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, AmerisourceBergen leverages this comprehensive contract vehicle to supply pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency requirements and other federal healthcare systems globally. The current award for Dupixent, an immunosuppressive medication used to treat conditions such as atopic dermatitis and eosinophilic asthma, demonstrates the company's continued role in delivering specialty medications essential to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.7k | 11/4/25 |